COSCIENS Biopharma Inc. - Rentabilitas operasi CSCI

COSCIENS Biopharma - logo grafis emiten CSCI

Core business margins for COSCIENS Biopharma Inc. (CSCI) are available for analysis on GURU.Markets, where the value -152.60 determines the parameter status against a backdrop of low profit scaling due to promotion costs. The business relies on long-term endocrinology patents to maintain superprofits. Growth is based on ophthalmology and oncology licenses in Canada and Latin America, which ensure high profitability.

CSCI: Margin operasi cosciensbio.com 10.08.2024 - 14.09.2025

Rincian metrik lan analitis perusahaan cosciensbio.com (CSCI)

- rega lan prakiraan konsensus rega:
Analisis wiwitan perusahaan:COSCIENS Bio, CSCI
Barang utama COSCIENS Biopharma Inc.

For COSCIENS Biopharma Inc. (CSCI), which focuses on developing orphan drugs and diagnostic software, controlling R&D and commercialization costs is critical. Analyzing the operating profitability of operational processes allows for an assessment of the share of core business profit in earnings before interest and taxes, revealing cost management efficiency and the resilience of the business model during periods of expensive borrowed capital.